key: cord-0753071-h9riwo09
authors: Wilson, W. Wyatt; Bardossy, Ana C.; Gable, Paige; Herzig, Carolyn; Beshearse, Elizabeth; Gualandi, Nicole; Sabour, Sarah; Brown, Nicole; Brown, Allison C.; Kutty, Preeta; Tobin-D'Angelo, Melissa; Lea, Janice P.; Apata, Ibironke W.; Novosad, Shannon; Hudson, Matthew; Hernandez-Romieu, Alfonso C.; Tobolowsky, Farrell; Lyons, Amanda; Gilbert, Sarah; Soda, Elizabeth; Biedron, Caitlin; Korhonen, Lauren
title: Absence of SARS-CoV-2 infections among patients with end-stage renal disease following facility-wide testing in four outpatient hemodialysis facilities
date: 2021-08-08
journal: Am J Infect Control
DOI: 10.1016/j.ajic.2021.07.022
sha: 2727b11266f68331822ca0f886c321ed5ae08e1e
doc_id: 753071
cord_uid: h9riwo09

Facility-wide testing performed at four outpatient hemodialysis facilities in the absence of an outbreak or escalating community incidence did not identify new SARS-CoV-2 infections and illustrated key logistical considerations essential to successful implementation of SARS-CoV-2 screening. Facilities could consider prioritizing facility-wide SARS-CoV-2 testing during suspicion of an outbreak in the facility or escalating community spread without robust infection control strategies in place. Being prepared to address operational considerations will enhance implementation of facility-wide testing in the outpatient dialysis setting.

escalating community spread without robust infection control strategies in place. Being prepared to address operational considerations will enhance implementation of facility-wide testing in the outpatient dialysis setting. The role of asymptomatic SARS-CoV-2 transmission has been described in the community and longterm care facilities (3) . Despite reports of high asymptomatic SARS-CoV-2 infection rates among patients with ESRD, the contribution of asymptomatic transmission in outpatient hemodialysis facilities is not well understood (4) . Currently, there are no recommendations for testing asymptomatic hemodialysis patients in the absence of known exposures or a facility outbreak. Given considerations for expanded testing strategies of asymptomatic individuals in other congregate settings, the purpose of this project was to assess the usefulness of facility-wide testing in determining the SARS-CoV-2 burden in an outpatient hemodialysis facility without evidence of transmission within the facility and to describe the logistical considerations required for successful implementation (5) .

Facility-wide SARS-CoV-2 testing was conducted at four outpatient hemodialysis facilities within the same healthcare system in Atlanta in August 2020. Testing was conducted over a two-week period between August 13 th through August 28th, during which community incidence of SARS-CoV-2 infections decreased from 450 to 250 cases per 100,000 population(5) and community prevalence declined to 10% positivity per week(6). Operational considerations for facility-wide testing are included in Table 1 . Table 1 . Operational considerations for and steps and strategies implemented during facility-wide testing for SARS-CoV-2 at outpatient dialysis facilities*

Steps and strategies Facility layout and sample collection Identify a location for sample collection that will minimize potential exposure to patients and healthcare personnel during collection of respiratory samples o A separate area inside the facility with a door that could be closed (i.e., exam room) and that was not being used for other purposes or a designated area outside the facility (i.e., for patients with stretchers) was used for sample collection o Staff remained flexible and adjusted the sample collection location for some patients, particularly those with mobility issues Ventilation, including directional airflow and air exchanges, in the sample collection area was reviewed † -During sampling, patients faced away from other patients and from equipment to avoid dispersing respiratory droplets if coughing or sneezing. Tissues were available for patients to cover any coughs or sneezes -Patient wore masks for duration of specimen collection procedure, only removing them just before sample collection and immediately replacing it once sample collection was complete -If patients coughed or sneezed on supplies or equipment (e.g., table), equipment was cleaned and disinfected, or discarded if it could not be cleaned and disinfected -Efforts were made to identify at least two potential sample locations in a facility to help ensure timely sample collection could continue if an area needed to be temporarily closed

Define roles and responsibilities of staff in advance o Multiple individuals were needed on the day of testing to ensure all tasks were completed in a timely manner. For example, five to six staff were involved in sampling and questionnaire administration for a dialysis shift with 40-50 patients -Two staff were dedicated to sample collection -Two staff were involved in interviews -One to two staff were dedicated to overseeing the process (i.e., consenting, interviewing, and reminding patients to get tested prior to or following dialysis treatment)

Communicate facility-wide testing plans to patients in advance Ensure staff are prepared to explain the rationale behind facility-wide testing and sample collection procedures o Patients were told in advance that they should arrive 15 minutes ahead of their normal arrival time or anticipate staying 15 minutes after their dialysis treatment for sample collection o Trusted facility staff and other providers were involved in patient education

Review organization policies and determine how patient consent will be obtained (e.g., will patients be required to sign a consent form or will verbal consent be sufficient) Make a plan for approaching patients who are unable to provide consent (e.g., cognitive impairment)

o Consent forms were provided to patients in advance so they could review and be prepared to ask any questions on the day of testing 

Of 561 patients available to consent for participation, 361 (64%) consented to participate, 13 (2%)

were excluded for inability to consent due to cognitive impairment and 187 (33%) refused. Refusal data was available for 135 participants of which 48 (36%) provided no reason, 43 (32%) refused due to prior SARS-CoV-2 testing, and 10 (7%) refused citing distrust of the healthcare system. Among the 361 participants, there were no SARS-CoV-2 infections detected by rRT-PCR. Patient demographics exposures, and symptoms consistent with COVID-19 are included in Table 2 . 

SARS-CoV-2 testing among patients with ESRD receiving hemodialysis in facilities without evidence of an active outbreak documented no new SARS-CoV-2 infections. Other studies that have described facility-wide testing in hemodialysis facilities have indicated a high prevalence of SARS-CoV-2 infections but were the result of targeted and mandatory testing during an outbreak (7, 8) . In our assessment, participation was voluntary and could have biased selection against those who were at higher risk for disease. Patients who knew they were at risk or were concerned about changing dialysis sites or shifts due to a positive test might have refused. Thirty percent of patients refused participation, most commonly due to having a prior test. Some patients interpreted having ever been tested as sufficient for ruling out infection during the current assessment. Patient engagement and education strategies may improve patient compliance with currently recommended COVID-19 testing and prevention strategies (9) . Patients with COVID-19 were being cared for on a dedicated shift using transmission-based precautions. Each facility reported implementing all other CDC recommended COVID-19 infection prevention control (IPC) practices, including requiring all patients to wear a face mask or cloth covering during their dialysis session. While our assessment did not specifically evaluate compliance with these measures, they have been associated with a decrease in SARS-CoV-2 infections in dialysis facilities (8) .

Furthermore, the decreasing SARS-CoV-2 incidence in the community may have decreased the likelihood of patient exposure to SARS-CoV-2 outside the facility and subsequent risk for pre-symptomatic or asymptomatic transmission once patients returned to the facility for dialysis.

While nearly half of the participants reported at least one symptom consistent with COVID-19 in the preceding 14 days, most symptoms were non-specific and are frequently reported by patients presenting to dialysis (10) . To our knowledge, there were no positive screens during routine temperature and COVID-19 symptom screening at the facility entrance during our assessment. The discrepancy between reported symptoms at the entrance screening and during the assessment is likely multifactorial but may represent the role that a clinical encounter may have in eliciting patient information compared to a screening process. The frequency of symptoms highlights the role that healthcare providers have in assessing patient symptoms to determine the need for SARS-CoV-2 testing and patient isolation.

Our assessment has several limitations. We used a convenience sample of patients and results may not be generalizable to other facilities. Of those who refused participation, we were not able to obtain further information (e.g., demographics, place of residence) other than the stated reason for refusing to participate, limiting our ability to identify factors to improve participation during facility-wide testing.

Implementation did not coincide with a high community incidence or suspected facility transmission, which limits our ability to better define specific indicators for facility-wide testing. Furthermore, we did not perform subsequent testing that may have identified initially missed cases. However, in the two weeks following testing, only two patients across all facilities were diagnosed with COVID-19. Finally, our assessment did not include healthcare personnel, which would be important for facility-wide testing following suspected facility transmission.

Results of this assessment suggest that facility-wide SARS-CoV-2 testing in hemodialysis facilities with IPC practices implemented may yield few positives in the absence of indicators of facility transmission. Instead, SARS-CoV-2 testing could be reserved for facilities with evidence of an outbreak or those facilities without robust strategies during escalating community spread. Understanding the logistics needed to successfully perform facility-wide testing remains important as the COVID-19

pandemic evolves and to ensure dialysis facility preparedness for future infectious disease outbreaks and pandemics.

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

COVID-19 in Patients on Maintenance Dialysis in the Paris Region

High prevalence of asymptomatic COVID-19 in haemodialysis: learning day by day in the first month of the COVID-19 pandemic

COVID-19 Antibodies and Outcomes Among Outpatient Maintenance Hemodialysis Patients

Guidance for Expanded Screening Testing to Reduce Silent Spread of SARS-CoV-2

COVID-19 Outbreak in an Urban Hemodialysis Unit

Shared Hemodialysis Care: Increasing Patient Involvement in Center-Based Dialysis

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Preventions (CDC).